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Abstract
Background: Deregulation of the phosphatidylinositol 3-kinases (PI3K)/Akt/mammalian target of rapamycin (mTOR)
pathway plays a central role in tumor formation and progression, providing validated targets for cancer therapy. S9, a hybrid
of a-methylene-c-lactone and 2-phenyl indole compound, possessed potent activity against this pathway.
Methodology/Principal Findings: Effects of S9 on PI3K-Akt-mTOR pathway were determined by Western blot,
immunofluorescence staining and in vitro kinas assay. The interactions between tubulin and S9 were investigated by
polymerization assay, CD, and SPR assay. The potential binding modes between S9 and PI3K, mTOR or tubulin were
analyzed by molecular modeling. Anti-tumor activity of S9 was evaluated in tumor cells and in nude mice bearing human
cancer xenografts. S9 abrogated EGF-activated PI3K-Akt-mTOR signaling cascade and Akt translocation to cellular
membrane in human tumor cells. S9 possessed inhibitory activity against both PI3K and mTOR with little effect on other
tested 30 kinases. S9 also completely impeded hyper-phosphorylation of Akt as a feedback of inhibition of mTOR by
rapamycin. S9 unexpectedly arrested cells in M phase other than G1 phase, which was distinct from compounds targeting
PI3K-Akt-mTOR pathway. Further study revealed that S9 inhibited tubulin polymerization via binding to colchicine-binding
site of tubulin and resulted in microtubule disturbance. Molecular modeling indicated that S9 could potentially bind to the
kinase domains of PI3K p110a subunit and mTOR, and shared similar hydrophobic interactions with colchicines in the
complex with tubulin. Moreover, S9 induced rapid apoptosis in tumor cell, which might reflect a synergistic cooperation
between blockade of both PI3-Akt-mTOR signaling and tubulin cytoskeleton. Finally, S9 displayed potent antiproliferative
activity in a panel of tumor cells originated from different tissue types including drug-resistant cells and in nude mice
bearing human tumor xenografts.
Conclusions/Significance: Taken together, S9 targets both PI3K-Akt-mTOR signaling and microtubule cytoskeleton, which
combinatorially contributes its antitumor activity and provides new clues for anticancer drug design and development.
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Introduction
Phosphatidylinositol 3-kinase (PI3K) plays a central role in a
complex, multi-armed signaling network that orchestrates cell
response including cell survival, growth, proliferation, angiogen-
esis, migration and glucose metabolism [1,2]. PI3K is presumed to
activate most of its downstream targets via the Akt protein, which
phosphorylates diversified downstream substrates including the
mammalian target of rapamycin (mTOR) [2], a master regulator
of protein translation. Moreover, PI3K and its downstream
components cross-talk with a number of other pathways, such as
the Raf/mitogen-activated protein kinase kinase/extracellular
signal–regulated kinase (MEK/ERK)–activated pathways [3].
PI3K-mediated signaling network is important in tumorigenesis
and progression, which is frequently hyper-activated in a variety of
human cancers, as a result of gain-of-function in PI3K,
inactivation of the lipid phosphatase PTEN or deregulated growth
factor signaling [1,3,4]. As such, the PI3K-Akt-mTOR pathway
has been validated as a tumor therapeutic target of increasing
interests.
Multiple efforts are under way in academia and industry to
develop clinically relevant inhibitors of this signaling pathway.
Temsirolimus (ToriselH, Wyeth pharmaceuticals), an analog of
rapamycin targeting mTOR [5], represents the most successful
PLoS ONE | www.plosone.org 1 March 2009 | Volume 4 | Issue 3 | e4881developed compounds targeting this pathway, which has been
approved for the treatment of advanced kidney cancer. Two other
rapamycin derivatives RAD-001[6] and AP-23573 are currently in
phase III clinical trials. With an increasing understanding of the
feedback loops exiting in the PI3K-Akt-mTOR pathway, it has
been recognized that inhibition on one output costs at the expense
of activation of the others. For instance, rapamycin monotherapy
activatesAktthroughinhibitionofanmTOR-dependentretrograde
signal [7]. For this reason, there is a growing consensus that the
inhibition of combined components in the PI3K-Akt-mTOR
pathway likely reflects a mechanistic rationale for the therapeutic
options. As a matter of fact, many of the most effective PI3K-Akt-
mTOR-targeted cancer therapies owe their activity to inhibition of
dual or multiple components in this pathway, such as NVP-BEZ235
(a dual pan-PI3K/mTOR inhibitor) and SF-1126 (inhibitor of all
isoforms of PI3K and other PIKK family members), which are now
entering into Phase I/II clinical trials [4].
Given the severity of most cancers and their high unmet clinical
need, together with the fact that the PI3K-Akt-mTOR axis
represents an important emerging class of drug targets, we
designed and synthesized a series of hybrids of a-methylene-c-
lactones and 2-phenyl indoles with the aim of discovery of new
inhibitor(s) targeting PI3K-Akt-mTOR pathway [8]. Of them, S9
stood out by functioning as a dual PI3K and mTOR inhibitor and
also a microtubule destabilizer. The converged outcome of both
cytostatic and cytotoxic identities of S9, together with its
appreciable in vivo antitumor profiles, help prove to be a promising
novel chemical template for the development of axis inhibitors.
Results
S9 inhibits PI3k-Akt-mTOR signaling
S9 restrains PI3k-Akt-mTOR signaling stimulated by EGF
in cancer cells. We have previously reported that S9 potently
down-regulated phosphorylation of Akt, mTOR, p70S6K and 4E-
BP1 upon stimulation with EGF in Rh30 cells [8]. To gain insight
of the effect of S9 on the PI3k-Akt-mTOR signaling, Rh30 cells
were exposed to various concentrations of S9 followed by EGF
stimulation. Although located in the upstream of this pathway,
phosphorylation of PDK-1 at Ser 241 was insensitive to serum
deprivation or EGF stimulation (Fig 1A), which is consistent with
the observation reported elsewhere [9]. Phosphorylation of PDK-1
was slightly depressed in the presence of 40 mM S9. In contrast, S9
significantly inhibited phosphorylation of Akt at both Ser 473 and
Thr 308 (Fig 1A). Compared with Ser473, Thr308
phosphorylation was more vulnerable to S9 treatment, which
might be due to phosphorylation of Ser 473 prior to the
phosphorylation at Thr 308 and is important for the recognition
and activation of Akt by PDK-1 [10]. Similarly, S9 abrogated
phosphorylation of mTOR at Ser 2448 and its downstream
proteins p70S6K at Thr 389 and 4E-BP1 at Thr 37/64 and Thr
70 in a concentration-dependent manner. The inhibitory activity
of S9 on the PI3K-Akt-mTOR signaling was also confirmed using
ovary carcinoma SKOV-3 cells (Fig 1B). Inactivation of the PI3K-
Akt-mTOR pathway was also reflected by decrease in the kinase
activities of PI3K, Akt and mTOR in the RH30 cells after S9
treatment (Fig S1).
S9 blocks Akt cellular translocation and cell membrane
ruffling. When cell is stimulated with growth factor, such as
insulin, insulin-like growth factor (IGF) and EGF, Akt aggregates
around cell membrane responding to recruitment by PIP3, which
was a catalytic product of activated PI3K. Activation of PI3K also
induces cell membrane ruffling [11]. Once the activity of PI3K is
harshly prohibited, aggregation of Akt and membrane ruffling
disappears even under growth factor stimulation. As shown in
Figure 1C, addition of IGF triggered Akt to aggregate on
membrane in EGFP-Akt-stably-transfected CHO cells deprived
of serum, demonstrated as highly fluorescent foci near the
membrane (blue arrow). Membrane ruffling (white arrow) was
also observed in these cells after IGF treatment. However,
exposure of cells to S9 before IGF stimulation abrogated Akt
translocation and membrane ruffling (Fig. 1C). The granule
intensity in each cell was measured and statistically analyzed by IN
Cell Analyzer workstation version 3.2. As shown in Figure 1D, S9
reduced the intensity of Akt granule in a concentration-dependent
manner. S9 also inhibited PI3K activity and block membrane
ruffling in Rh30 cells (Fig S2).
S9 inhibits the catalytic activities of PI3K and mTOR. As
S9 inhibits the PI3K-Akt-mTOR pathway signaling cascade,
PI3K kinase assays were first carried out to determine whether S9
inhibits the catalytic activity of PI3K. PI3K were activated with
EGF and immunoprecipitated from Rh30 cells, and kinase assays
were performed in the presence of S9. As shown in Figure 2A, the
ability of PI3K to generate PIP3 decreased after S9 treatment in a
concentration-dependent manner and the activity decreased to
53.2% in the presence of 1 mM S9. Since S9 is capable of
inhibiting the activity of PI3K, we detected whether S9 inhibits the
activity of mTOR, which bears a highly homologous COOH-
terminal catalytic domain with PI3K. As shown in Figure 2B,
phosphorylation of 4E-BP1 by mTOR was greatly down-regulated
by S9 treatment. 1 mM S9 decreased mTOR kinase activity by
58.7%. Thus, S9 is a new dual inhibitor of PI3K and mTOR.
Rapamycin and its derivatives, which specifically inhibit
mTOR, induced rapid Akt (Ser473) phosphorylation both in
cancer cells and in clinical patient tumors [7], presumably due to
inhibition of a mTOR-dependent retrograde signal [12]. This
effects evoked impugnation for rapamycin and its derivatives’
application in clinical cancer therapy. As shown in Figure 2C,
rapamycin treatment induced up-regulation of Akt phosphoryla-
tion at Ser 473 in Rh30 cells, with no influence on phosphory-
lation at Thr 308, which was consistent with previous report [13].
Although S9 is able to inhibit the activity of mTOR, S9 treatment
alone does not induce hyper-phosphorylation of Akt at Ser 473
(Fig. 2C). Moreover, co-current treatment with S9 and rapamycin
completely attenuated the hyper-phosphorylation of Akt at Ser
473 induced by rapamycin (Fig. 2C), indicating S9 could
circumvent activation of Akt triggered by mTOR inhibition.
S9 blocks ATM- and ATR-regulated DNA repair
pathways. ATM, ATR and DNA-PK, which are involved in
DNA damage response, also belong to the phosphoinositide 3-
kinase-related kinases (PIKK) family and share highly homologous
catalytic domain with PI3K and mTOR. We next determined the
effect of S9 on the activities of ATM, ATR and DNA-PK by
measuring the level of phosphorylated H2AX (cH2AX). H2AX
could be quickly phosphorylated by ATM, ATR and DNA-PK
upon DNA strand breaks induced by CPT [14]. As shown in
Fig 2D, Rh30 cells displayed a robust increase in cH2AX level
after exposure to CPT for 1 h. Co-treatment with S9 significantly
abrogated the up-regulation levels of cH2AX at concentrations
above 50 mM, indicating that S9 also inhibited the kinase activity
of ATM, ATR or/and DNA-PK in Rh30 cells.
To determine the selectivity of S9 on kinases, we tested the
effect of S9 on 9 tyrosine kinases and 21 serine/threonine kinases.
We found that S9 possessed weak or no inhibition on the tested
kinase panel (Table S1), indicating S9 is selective against PI3K and
mTOR, and against ATM, ATR and DNA-PK as well.
S9 potentially binds to PI3K and mTOR. Based on the
facts that most PI3K inhibitors apparently bind to the ATP-
S9 Targets PI3K/mTOR/Tubulin
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S9 is a pan-inhibitor for PIKK family members, molecular
docking approach was performed to predict their potential binding
sites and possible binding mode between S9 and p110a (Figure 2E).
The docking results indicated that S9 could bind to the ATP
pocket with high affinity. For a better resolution, a close-up view of
the binding interface was developed. S9 forms one hydrogen-bond
with the main-chain of Tyr 836 and hydrophobically interacts
with Trp 780, Ile 800, Ile 848, Ile 850 and Val 851 of the enzyme.
In addition, overall arrangements of S9 and ATP are very similar
comparing their binding modes in the active site of PI3K.
Likewise, the S9 hydrogen bonds to the Thr 2245, Lys 2187 and
His 2447 of the enzyme in the mTOR-S9 complex (Figure 2F).
Among them, Lys2187, which are highly conserved in PIKK
Figure 1. S9 inhibits PI3K-Akt-mTOR signaling. A–B), S9 depresses EGF-triggered activation of PI3K-Akt-mTOR signaling pathway. Serum-
deprived Rh30 cells (A) and SK-OV-3 cells (B) were treated with indicated concentrations of S9 for 1 h followed by EGF (50 ng/ml) stimulation for
10 min. Cells were harvested for Western blot analysis with antibodies specific for p-PDK1 (S241), PDK, p-Akt (T308), p-Akt (S473), Akt, p-mTOR
(Ser2448), mTOR, p-p70S6K (T389), p70S6K, p-4E-BP1(T37/64), p-4E-BP1 (T70), 4E-BP1 and actin. Arrows indicate p70 isoform of S6 kinase protein. C)
S9 blocks Akt membrane translocation and membrane ruffling. CHO (pCORON1000-EGFP-Akt) cells seeded on chamber were starved for 2 h then
treated with 5 or 10 mM S9 for 1 h followed by IGF stimulation for 5 min. Fluorescent pictures were captured with confocal fluorescent microscopy.
White arrows indicate cell membrane ruffling. Blue arrows indicate fluorescent foci. D) Total Akt granule intensity in each CHO (pCORON1000-EGFP-
Akt) cell was counted with statistic module by IN Cell Analyzer 1000. Data shown are representative from two independent experiments.
doi:10.1371/journal.pone.0004881.g001
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results provide us a clue that S9 may directly target PI3K and
mTOR.
S9 perturbs microtubule skeleton via binding to
colchicine-binding sites of tubulin
S9 arrests tumor cells in M phase. As a common
consequence of PI3K-Akt-mTOR signaling inhibition, decreased
expression of cyclin D1 will blockade cell cycle transition in G0/
G1 phase [17,18]. To explore the effect of S9 on cell cycle
distribution, SKOV-3 cells were treated with indicated
concentrations of S9 for 24 h. As shown in Figure 3A, S9
unexpectedly arrested cells in G2/M phase in a concentration-
dependent manner up to 5 mM. Cell population in G2/M phase
decreased, accompanied with increase in cell population in G1
phase in the presence of 10 mM of S9, which could be a result
from PI3K-Akt-mTOR inhibition. S9 also arrested SK-OV-3 cells
in G2/M phase time-dependently (Fig. 3A, lower panel). To
examine whether the S9-induced G2/M arrest was reversible,
SKOV-3 cells were treated with S9 for 16 h (T16) and then S9
was washed out, followed by 24 h (R24) additional incubation in
fresh media. We found that the cells arrested in G2/M phase
could not re-enter the normal cell cycles progress (Fig. 3B),
indicative of irreversible G2/M phase arrest by S9.
To differentiate whether S9 induced G2 phase or M phase
arrest, SKOV-3 cells were treated with S9 and stained with anti-
Cyclin B1 antibody. Persistent residence of cyclin B1 in nuclei is an
indication of cell mitosis block, as well as a marker to distinguish M
Figure 2. S9 inhibits the kinase catalytic activity of PI3K and mTOR. A–B) Active kinases were immunoprecipitated from exponentially
growing Rh30 cells and kinase assays were performed. In the presence of indicated concentrations of S9, phosphorylation PIP2 to PIP3 were
measured by ELISA (A). Phosphorylation of 4E-BP1 (B) was detected by Western blot. Band intensity was quantitated by optical densitometric analysis
and normalized to vehicle control. Representative images were presented and relative kinase activity was plotted as mean6SD of three independent
experiments. C) S9 abrogates rapamycin-induced hyperphosphorylation of Akt (Ser 473). Rh30 cells were starved overnight and treated with 10 mM
of S9 and/or rapamycin (Rapa) for 1.5 h on the next day, followed by stimulation with 50 ng/ml EGF for 10 min. Phosphorylated Akt at Serine 473 and
Threonine 308 and total Akt were detected by Western blot. D) Rh30 cells were exposed to 10 mM camptothecin (CPT) for 1 h after pre-incubation
with indicated concentrations of S9 or wortmannin (Wort) for 30 min. Cells were collected and c-H2AX levels were detected with Western blot
analysis. E–F) The binding mode of S9 within PI3K (E), mTOR (F). The protein is represented by cartoon. The residues interacting with the compounds
are shown in sticks. All of the structural diagrams were prepared using PyMOL (http://pymol.sourceforge.net).
doi:10.1371/journal.pone.0004881.g002
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aggregated in nuclei after S9 treatment, indicating that S9 induced
M phase arrest (Fig 3C). S9 treatment also resulted in decreased
phosphorylated cyclin B1 at Ser 147 and increased phosphorylated
cdc25c at Ser 216 and total cyclin B1 (Fig 3C), which is in
accordance with those agents that induce M phase arrest [20,21].
S9 disturbs cytoskeleton. The compounds which arrest
cells in M phase are mostly tubulin-targeting agents. We tested
whether S9 disrupted the organization of cytoskeleton. The
microtubule structure of S9-treated cells was visualized via
immunocytochemistry. As shown in Figure 4A, microtubule
formed intact network with fine mesh in untreated cells, while in
S9-treated cells, tubulin was dispersed as dot, and cells appeared as
weaker staining of anti-tubulin antibody which was presumably
due to reduction of microtubular materials by depolymerization
resulted from S9 treatment (Fig. 4A).
S9 inhibits tubulin polymerization in vitro and causes a
conformational change in tubulin. As S9 has been shown to
disturb microtubule cytoskeleton in SKOV-3 cells, we tested the
effects of S9 on tubulin polymerization in vitro. The polymerization
of purified tubulin at 37uC in the presence of tested compounds or
vehicle control was monitored spectrophotometrically. In the
absence of compounds, purified tubulin (15 mM) was polymerized
in a time-dependent manner. S9 treatment inhibited tubulin
polymerization in a concentration-dependent manner (Fig. 4B).
The effect of S9 on the second structure of tubulin was monitored
by far-UV CD spectroscopy. As shown in Figure 4C, 25 mMS 9
induced a secondary structure change of tubulin, characterized by
the alteration of a-helix and b-sheet content.
S9 directly bind to colchicine-binding site on
tubulin. Because S9 inhibits tubulin polymerization and
causes conformational change of tubulin, direct binding of S9 to
tubulin was next determined using SPR biosensor technology, with
a well-characterized tubulin destabilizer colchicine as a positive
control. Various concentrations (50.0, 35.0, 24.5, 17.2, 12.0, 8.40,
5.88 mM) of S9 and colchicine were injected for binding with
tubulin immobilized on the CM-5 sensor chips. Real time sensor
grams were recorded. As shown in Figure 4D, injection of S9 or
colchicine caused a significant increase in SPR response in a
concentration-dependent manner. General fitting and steady-state
binding affinity calculated with Biacore evaluation Version 3.0
software helped release a relative high binding affinity for tubulin
with the dissociation constant (Kd) value of 11.1 mM, which was
two-fold lower than that of colchicine (24.6 mM).
Most compounds that inhibit tubulin polymerization bind to
either colchicine- or vinblastine-binding sites[21]. We investigated
whether S9 binds to either of these two sites via competitive
binding assays. The intrinsic fluorescence of colchicine increases
upon binding to tubulin [22], which could be used as an index for
S9 competition with colchicine in tubulin binding. As shown in
Figure 4E, left panel, the fluorescence of colchicine-tubulin
complex reduced in the presence of S9 in a dose-dependent
manner, suggesting that colchicine failed to bind to tubulin-S9
complex. In contrast, the fluorescence remained unchanged when
vincristine, a typical vinblastine-binding site drug, was incubated
with colchicine and tubulin. A fluorescent analogue of vinblastine
(BODIPY FL-vinblastine) was employed to detect whether S9
bound to vinblastine-binding site. S9 had no effect on the
Figure 3. S9 arrests tumor cells in M phase. A) S9 induces does-dependent and time-dependent G2/M phase arrest. SK-OV-3 cells grown in
serum-supplemented medium were treated with S9 for 24 h. Cells were collected and subjected to FACS analysis. Data shown are percentage of cell
population in G2/M phase. B) S9-induced G2/M phase arrest is irreversible. SK-OV-3 cells were treated with S9 for 16 h (T16), and then S9 was washed
out. Cells were further incubated in fresh medium for 24 h (R24). Cells were collected and DNA content was analyzed by FACS analysis. C)
Aggregation of cyclin B1 in nucleus after S9 treatment. SK-OV-3 cells were exposed to 5 mM S9 for 24 h. Cells were fixed and stained with anti-
cyclinB1 antibody (green) and DAPI (blue). D) S9 decreases the level of phosphorylated cyclin B1 and increases phosphorylation of cdc25C. SK-OV-3
cells were exposed to 5 mM S9 for 24 h and western blot analyses for p-cyclinB1 (Ser 147), total cyclinB1, p-cdc25C (Ser 216) and cdc25C were
performed. Glyceraldehyde 3 phosphate dehydrogenase (GAPDH) served as a loading control.
doi:10.1371/journal.pone.0004881.g003
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reduced in the presence of vinblastine (Fig. 4E, right panel).
These findings provide the evidence that S9 directly binds to
colchicine-binding site but not vinblastine-binding site of tubulin.
The superimposed binding models of S9 and colchicine in
tubulin were next performed (Fig. 5). Despite their strikingly
difference in structures, the conformation of S9 occupies similar
Cartesian space in the colchicine site. Moreover, S9 hydrophobi-
Figure 4. S9 disturbs the microtubular structure by binding to tubulin directly and inhibiting tubulin polymerization. A) S9 disturbs
the cell skeleton structure. SK-OV-3 cells were exposed to 5 mM S9 for 24 h and stained with anti-tubulin antibody (green) and DAPI (blue). Scale bar:
30 mm. Data shown are representative of at least three independent experiments. B) Inhibition on purified tubulin polymerization by S9. Purified pork
tubulin was incubated with S9, vincristine (VCR) or colchicine (COL) or vehicle in reaction buffer. The optical density (OD) at 340 nm was measured
with a spectrophotometer every 1 min till the OD value became stable. C). Disruption secondary structure of tubulin by S9. Purified tubulin and
25 mM S9 were co-incubated in reaction buffer for 1 h. The circular dichroism (CD) spectra were recorded. The characterized absorbance wave
lengths were 209/222 nm for a–helix and 196 nm for b–sheet. D) S9 (left panel) and colchicines (right panel) bind to tubulin directly. Purified tubulin
was immobilized on sensor chip. Association and dissociation rate constants and real-time binding capacity were recorded by Surface Plasmon
Resonance (SPR). The Kd values were computed by Biacore evaluation Version 3.0 software. E) Competitive binding of S9 to colchicine-binding sites
on tubulin but not vinblastine-binding sites. Tubulin was co-incubated with indicated concentrations of S9 or vincristine for 1 h, then colchicine was
added (left panel). Right panel, tubulin was co-incubated with S9 or vinblastine (VLB) for 1 h followed by addition of BODIPY-FL-vinblastine. The
fluorescence was measured by spectrofluorometer. All assays were repeated twice and representative data were shown.
doi:10.1371/journal.pone.0004881.g004
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378, which interact similarly with colchicine. Of particular note,
the MOMO group, lying in the side chain of the phenylindole,
formed a hydrogen bond with Lys 254, which might offer a
conformation for S9 to place effectively in tubulin. In contrast, S7,
in which MOMO group is replaced by H [8], has no effect on
tubulin polymerization (data not shown).
S9 disrupts tumor cell growth in vitro and in vivo
S9 induces rapid apoptosis in human cancer
cells. Because S9 displayed potent inhibition on PI3K-Akt-
mTOR pathway as well as tubulin polymerization, the ability of
S9 to induce apoptosis was examined in various tumor cells. Cells
were subjected to annexin-V-PI doubling staining after exposure
to 10 mM S9 for 8 h. As shown in Figure 6C, tumor cells
underwent rapid apoptosis after exposure to S9 for 8 h. PI3K
inhibitors usually induce G1 phase arrest rather than apoptosis.
Rapid apoptosis induced by S9 might represent its combinatorial
effect on PI3K-Akt-mTOR pathway and microtubule
cytoskeleton.
S9 inhibits proliferation of a panel of tumor cells in
vitro. The anti-proliferative activity of S9 was measured with
SRB assay against a panel of human tumor cells, including oral
epidermoid cancer, lung cancer, liver cancer, colon cancer,
rhabdomyosarcoma, ovarian cancer, osteosarcoma, breast
cancer, cervix cancer, stomach cancer, prostate cancer and
leukemia cells. S9 displayed potent activity against the
proliferation of a broad spectrum tumor cells with a mean IC50
of 9 mM (Fig 6A). Wortmannin, a well-known PI3K inhibitor, was
taken as a reference drug with a mean IC50 of 16 mM. Although
both S9 and wortmannin target PI3K pathway, they displayed
different anti-proliferation profiles. For example, S9 were more
potent in K562 and U2OS cells than wortmannin. This advantage
was also observed in the mini-set of colon cancer cell lines (Fig. 6A).
Detailed IC50s were shown in Table S2.
The anti-proliferative activity in five pair of MDR cells,
Gleevec-resistant K562/G02 and rapamycin resistant Rh30/Rapa
cells was also evaluated. Remarkably, S9 demonstrated similar
inhibition in drug resistant cancer cells and respective parental
cells, with the resistant factors around 1(Fig 6B). Of particular
note, S9 remains active against MDR cells unlike other tubulin-
interacting drugs such as colchicine and vincristine (Fig 6B).
S9 inhibits the growth of human cancer xenografts on
nude mice. The anti-tumor activity of S9 in vivo was evaluated
using human rhabdomyosarcoma Rh30 and human hepatoma
SMMC 7721 xenografts models. After 14-day treatment of S9, the
relative tumor volume (RTV) of control group for Rh30 xenograft
was 9.24, while the RTV of group received S9 administration
(50 mg/kg) reduced to 5.26. Similar inhibitory effect was also
observed in SMMC7721 xenograft, with a T/C value of 0.52
(Fig. 6D). The body weights of nude mice reduced slightly after
administration of 50 mg/ml S9 for two weeks (data not shown),
indicating S9 held some extent of toxicity. However, S9-induced
toxicity was tolerable because less than 10% reduction in body
weight was observed on day 14 compared to day 0.
Discussion
S9, among a series of hybrids of a-methylene-c-lactones and 2-
phenyl indoles [8], stood out for its potent activity against PI3K-
Akt-mTOR signaling [8]. In this study, we identified its cellular
targets and characterized its mechanism of action. S9 was found to
abrogate EGF-activated PI3K-Akt-mTOR signaling cascade and
Akt translocation via its dual inhibition of both PI3K and mTOR.
S9 was further noted to inhibit the polymerization of tubulin and
thus cause M phase arrest. Such cooperation between blockade of
PI3-Akt-mTOR signaling and tubulin cytoskeleton contributes to
its anti-proliferative activity observed in vitro against a panel of
tumor cells including MDR tumor cells and in vivo antitumor
activity in mice bearing human tumor xenografts.
We found that S9 potently inhibited the kinase activity of PI3K
and mTOR, as well as DNA repair-related PIKK family members
and no effects on 30 tested kinases. Therefore, S9 was identified as
a selective dual inhibitor against PI3K and its downstream kinase
mTOR. PI3K and mTOR belong to the PIKK family, bearing a
significant homologous COOH-terminal catalytic domain. Mo-
lecular docking displayed that a-methylene-c-lactones moiety
represents a key element for binding to the ATP pocket of both
PI3Ka and mTOR, via hydrophobic interaction and hydrogen
bonds. Interestingly, such a a-methylene-c-lactone moiety also
harbors in wortmannin, which has been verified to be indispens-
able for its PI3K inhibition and anticancer activity [23]. This
notion helps substantiate the importance of a-methylene-c-lactone
moiety not only on inhibition of PI3K but also on mTOR as well.
Inhibitors of mTOR are currently being tested clinically and
have been somewhat disappointing as monotherapy against
cancer. Encouragingly, S9 significantly inhibited EGF-triggered
PI3K-Akt-mTOR signaling transduction and notably, circum-
vented rapamycin-induced hyperphosporylation of Akt. These
findings provide pharmacological evidence that retrograde-depen-
dent activation of Akt can be overcome by dual inhibition of PI3K
and mTOR, which in turn underscore that inhibition of PI3K and
mTOR in combination should be more effective than inhibition of
mTOR alone.
As an inhibitor of PI3K-Akt-mTOR pathway, it is out of our
expectation that S9 arrested tumor cells in M phase, which was
attributed to its disturbance of microtubule cytoskeleton. The
Figure 5. The binding mode of S9 within tubulin. The protein is
represented by cartoon. The residues interacting with the compounds
are shown in sticks. S9 and colchicine are also represented by sticks and
colored in cyan and yellow, respectively. All of the structural diagrams
were prepared using PyMOL (http://pymol.sourceforge.net).
doi:10.1371/journal.pone.0004881.g005
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further confirmed its activity of microtubule perturbation. It has
been reported that 2-phnylindole derivatives inhibited tubulin
polymerization by binding to the colchicines site on tubulin [24].
Consistently, the 2-phenylindole moiety interacted with tubulin in
our computational exercise, which occupies similar Cartesian
space in the colchicine site of tubulin, releasing similar
hydrophobic interactions to that of colchicine. Moreover, when
the MOMO group on the side chain of 2-phnylindole was
replaced by H in compound S7, no tubulin disturbance was
observed even though S7 possesses similar potency with S9 against
PI3K-Akt-mTOR signaling [8]. Thus, the hydrogen bond formed
between Lys 254 and the MOMO group is essential for S9 to
interact with tubulin. This scenario, together with the aforemen-
tioned findings, helps understand that a smart manipulation of 2-
phnylindole together with a-methylene-c-lactone might offer the
appreciable selectivity and targetability for S9.
The dramatic clinical efficacy of targeted inhibitors combined
with the cytotoxic drugs has long been hoped to revolutionize the
cancer therapy. In fact, inhibitors of PI3K-Akt-mTOR pathway
Figure 6. S9 displayed anti-tumor activity in vitro and in vivo and induces rapid apoptosis in human cancer cells. A) Antiproliferative
activity of S9 and wortmannin against a wide panel of tumor cell lines. IC50s plotted as mean6SD (mM) were from three separate experiments. B)
Resistance factor (RF) of S9 and reference compounds in drug-resistant cancer cells. RF was calculated as the ratio of the IC50 value of the drug-
resistant cells to that of the corresponding parental cells. C) S9 induces rapid apoptosis in human cancer cells. Rh30, A375, MKN-28 and U2OS cells
were treated with S9 for 8 h. Apoptosis was measured by Annexin V-PI double staining. Apoptosis measured as Annexin-V positive cells were plotted.
Data shown were mean6SD from three independent experiments. D) Rh30 (left panel) and SMMC7721 (right panel) xenograft growth inhibition after
administration of S9. Rh30 and SMMC7721 nude mice were subcutaneously inoculated with a tumor fragment. The animals were randomly divided in
groups when tumor volume reached 100 to 200 mm
3 and received i.p. injection of normal saline or S9 five times a week for two weeks. Tumor
volumes were measured and relative tumor volumes were calculated as tumor volumeDn/tumor volumeD0. Data shown are the mean of six mice.
doi:10.1371/journal.pone.0004881.g006
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by cytotoxic drugs including DNA damaging agents and tubulin
destabilizer [25]. This principle of concept appeals a surge of
interests in discovery of dual cytostatic and cytotoxic identities. In
current study, S9 induces rapid apoptosis in a number of tumor
cells. S9 also displays potent antiproliferative activity in MDR
cells, which is distinct in tubulin interfering drugs such as
colchicine and vincristine (Fig.6B). Moreover, S9 overcomes drug
resistance caused by low expression of 4E-BP1 or overexpression
of Bcr-Abl (Fig 6B) and circumvents Akt activation triggered by
mTOR inhibition. In contrast, S7, which failed to interfere the
structure of tubulin but with similar potency in impairing PI3K-
Akt-mTOR signaling, was less active against the proliferation of
Rh30 cells compared to S9 (data not shown). All these favor S9 to
possess synergistic cytostatic and cytotoxic efficacy and stand out
distinctly from the established PI3K-Akt-mTOR inhibitors or
known tubulin-interfering drugs.
In summary, we herein show for the first time that S9 functions
as a multi-inhibitor simultaneously targeting both PI3K-Akt-
mTOR axis and microtubule cytoskeleton. The converged
outcome of both cytostatic and cytotoxic paradigms of S9 in vitro
and in vivo, together with its appreciable anti-MDR profiles, help
prove to be a promising alternative template for rational designing
of anticancer drugs. Given the family of PI3K inhibitors could
impact such general processes as insulin signaling, diabetes,
obesity, and aging, unwanted side-effects should be carefully
considered. In regards to these potential toxicities, we believe that
optimal drug candidates that is more potent with improved water-
solubility derived from S9 must be evaluated extensively for both
efficacy and safety in cellular and animal systems.
Materials and Methods
Chemicals
Wortmannin, colchicine, vinblastine and vincristine were
purchased from Sigma (St. Louis, MO), triciribine from Biomol
(Plymouth Meeting, PA) and rapamycin from LclLab (Woburn,
MA), fluorescent vinblastine (BODIPY FL-vinblastine) from
Invitrogen (Eugene, OR). S9 (Fig. 1) was prepared as described
previously [8] with a purity .99.5%. Each compound was
dissolved in dimethyl sulfoxide (DMSO) at the concentration of
10 mM. Aliquots were stored at 220uC. All the compounds were
diluted to desired concentrations immediately before each
experiment.
Cell Lines and Culture Conditions
Human colorectal carcinoma LOVO, human breast carcinoma
MDA-MB-468, human prostate carcinoma PC3, human osteo-
sarcoma U2OS cells were from American Type Culture
Collection (ATCC, Manassas, VA); human lung adenocarcinoma
NCI-H23 cells were obtained from the National Cancer Institute
(NCI); rhabdomyosarcoma (RMS) Rh30 cells were generous gift
from Dr. P.J. Houghton (St. Jude Children’s Research Hospital,
Memphis, TN). MDA-MB-468, Rh30, LOVO, NCI-H23 and
U2OS cells were grown in RPMI-1640 medium supplemented
with 10% (v/v) fetal bovine serum (FBS; GIBCO, Grand Island,
NY), 2 mM L-glutamine, 100 U/ml benzylpenicillin, 100 mg/ml
streptomycin and 10 mM HEPES (pH 7.4). PC3 cells were grown
in Ham’s F12 (GIBCO, Grand Island, NY) with 10% FBS. CHO
(pCORON1000-EGFP-Akt) was purchased from GE Healthcare
(EGFP: Enhanced Green Fluorescence Protein) and propagated in
F-12 Ham medium with Glutamax supplemented with 10% FBS,
penicillin-streptomycin (50 U/ml) and geneticin (0.5 mg/ml,
Sigma-Aldrich, St. Louis, MO). Rest of cells used in this study
were grown as described previously [26]. All cells were cultured in
a highly humidified atmosphere containing 5% CO2 at 37uC.
Western Blot analysis
Rh30 and SK-OV-3 cells were seeded at density of 5610
5 cells/
well in six-well plates. Cells were washed twice with serum-free
medium on the next day and further incubated in serum-free
medium for 24 h. Cells were exposed to S9 or wortmannin for 1 h
before stimulation with 50 ng/ml epithelial growth factor (EGF,
R&D system, Minneapolis, MN) for 10 min. Cells were collected
and subjected to western analysis as described [26], using antibodies
against phosphorylated PDK1 at serine 241, phosphorylated Akt at
threonine 308 (#9275) or serine 473 (#9271), phosphorylated
mTOR at serine 2441 (#2971), phosphorylated p70S6K1 at
threonine 389 (#9209) and phosphorylated 4E-BP1 at threonine
37/46 (#9459)or 70 (#9455) (Cell Signaling Technology, Wal-
tham, MA). Membranes detected phosphorylated proteins were
stripped with Re-blot plus mild solution (Chemicon International,
CA) and re-blotted with antibodies against corresponding total
PDK1 (#3062), Akt (#9272), mTOR (#2972), p70S6K1(#9202)
and 4E-BP1 (#9452). For detection cH2AX, Rh30 cells were
treated with DMSO or 10 mM camptothecin for 1 h following
incubated with indicated concentrations of S9 or wortmannin for
30 min. Cells were collected and subjected to Western blot analysis
using antibodies against c-H2AX (#9718). b-actin (#4967) or
GAPDH (Kangchen, China) were used as loading control.
Immunoprecipitation and Kinase Assays
Rh30 cells were treated with EGF 50 ng/ml for 10 min after
incubated in serum-free medium for 24 h. Cells were then lysed in
buffer containing 50 mM Tris-HCl (pH 7.4), 100 mM NaCl,
50 mM b-glycerophosphate, 10% glycerol (w/v), 1% Tween-20
(w/v), 1 mM EDTA, 10 mg/mL aprotinin, 1 mg/ml pepstatin A,
10 mg/ml leupeptin, 2 mM phenylmethylsulfonyl fluoride, 20 nM
microcystin-LR and 25 mM NaF. Cell lysates were clarified by
centrifugation at 17,500 g for 15 min at 4uC. One mg of the cell
protein was used for immunoprecipitation. Immuno-complexes
were suspended in kinase buffer [10 mM HEPES (pH 7.4),
50 mM NaCl, 50 mM b-glycerophosphate, 10% glycerol (w/v),
10 mM MnCl2, 1 mM DTT]. Protein A/G agarose beads slurry
was equally divided into 5 aliquots, mixed with vehicle or different
concentrations of S9. mTOR kinase assay was performed with
50 mM ATP and 1 mg recombinant 4E-BP1 (A.G. Scientific, San
Diego, CA). Reactions were terminated by adding 56SDS loading
buffer and samples were separated on SDS PAGEs. Phosphory-
lation of 4E-BP1 was visualized with Western blot analysis. Band
optical densitometric (OD) analysis was performed using ImageJ
(http://rsb.info.nih.gov//ij/) and relative kinase activity was
calculated with the formula: ODdrugs/ODEGF6100%. The mean
values were obtained from at least 3 independent tests.
Enzyme Linked Immunosorbent Assays (ELISAs)
Effect of S9 on PI3K activity was measured by PI3K ELISA kit
(Echelon Biosciences Inc., Salt Lake City, UT) according to the
manufacturer’s instructions. PI3K was immunoprecipitated using
an anti-human PI3K p85 subunit antibody (Santa Cruz Biotech-
nology, Inc., CA) and kinase assay was initiated in the presence of
PtdIns(4,5)P2 substrate and ATP (25 mM). The relative PI3K
activity was computed as (PIP3S9/PIP3control)6100%.
Akt translocation Assay
The CHO (pCORON1000-EGFP-Akt) cells were seeded in a
96-well black plate (Corning, NY 14831). On the next day, cells
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different concentrations of S9 dissolved in assay buffer containing
2 mM Hoechst 33342 for 1 h. Insulin-like growth factor 1 (IGF-1
10 ng.ml
21) was added to trigger Akt membrane translocation.
Images were captured by IN Cell Analyzer 1000 (GE Healthcare)
with 475/535 nm excitation/emission filters 5 min later. Each
tested concentration was repeated in 12 wells and total granule
intensity of EGFP-Akt foci in each cell were measured and
quantitated by statistic software module.
Fluorescent Microscopy
SKOV-3 cells were grown on 1.561.5 cm
2 glass chamber slides
and treated with 5 mM S9 for 24 h. Immunofluorescent staining
with anti-cyclin B1 antibody (Santa Cruz Biotechnology, Inc., CA)
or anti-tubulin antibody (Invitrogen, Eugene, OR) was visualized
as described [26].
Fluorescence Activated Cell Sorter (FACS) Assay
DNA content was measured with a FACS-Calibur cytometer
(Becton Dickinson, San Jose, CA) and cell cycle distribution were
calculated as described previously [27]. Apoptosis were detected
with Annexin V-FITC apoptosis detection kit (Beckon Dickinson
Labware, Bedford, MA) and fraction of Annexin V positive cells
was measured with Cell Quest Software. Each experiment was
repeated thrice.
Purified Tubulin Assembly Assay
Pork tubulin was isolated, purified and stored as reported [28].
Prepared tubulin (15 mM) was mixed with different concentrations
of S9, colchicine or vincristine in PEM buffer (100 mM PIPES,
1 mM MgCl2, and 1 mM EGTA) containing 1 mM GTP and 5%
glycerol. Microtubule polymerization was monitored at 37uCb y
light scattering at 340 nm using a VERSAmax multiwell
spectrophotometer [27].
Circular dichroism (CD) spectroscopy
CD spectroscopy was performed as described [27]. Briefly,
3 mM tubulin was incubated with 25 mM S9 in PEM buffer at
37uC for 1 h. CD spectra were recorded on a Jasco-810
spectropolarimeter (Jasco, Tokyo, Japan) at 25uC.
Competitive tubulin-binding Assay
For colchicine competitive binding assay, tubulin was co-
incubated with indicated concentrations of S9 or vincristine at
37uC for 1 h. Then colchicine was added to a final concentration
of 5 mM. For BODIPY-FL-vinblastine competitive binding assay,
BODIPY FL-vinblastine was added to S9-tubulin or vinblastine-
tubulin binding equilibria. Fluorescence was determined using a
Hitachi F-2500 spectrofluorometer (Tokyo, Japan) at excitation
wavelengths of 365 nm and emission wavelengths of 435 nm or
502–528 nm for BODIPY-FL vinblastine. Blank values (buffer
alone) as background were subtracted from all samples.
Surface Plasmon Resonance (SPR) Assay
The binding affinities of S9 or colchicine to the tubulin were
determined using the SPR biosensor technology. The purified
tubulin (Cytoskeleton, Denver) were immobilized to CM5 chip
surface by standard Biacore procedure using HBS-EP buffer
(10 mM HEPES, 150 mM NaCl, 3.4 mM EDTA, and 0.005%
(v/v) surfactant P20, pH 7.4) as running buffer. The specific
binding profiles of S9 and colchicine to the immobilized tubulin
were obtained after subtracting the response signal from the
control flow cell. All the data were collected at 25uC with running
buffer HBS-EP at a constant flow of 30 ml/min. Binding affinities
of the compounds to tubulin were evaluated with Biacore
evaluation Version 3.0 software (GE Healthcare, Wisconsin,
USA).
Molecular Modeling of the S9-protein Complex
The crystal structures of the PI3K-a [Protein Data Bank (PDB)
Code: 2RD0][29], tubulin-colchicine complex (PDB Code:
1SAO)[30] were obtained as the target structures in the molecular
docking. The sequence of mTOR was retrieved from the Swiss-
Prot database and the crystal structure of the PI3K-a [29] was
used as the template structure for homology modeling of mTOR
structure. The sequence identity in catalytic domain between
mTOR and PI3K-a is about 29%. The ClustalW algorithm [31]
and the Homology module of InsightII (version 2000 Accelrys San
Diego CA) were applied in sequence alignment, and the best-fit
alignment was obtained based on the Blosum scoring matrix [32]
and previous alignments [16]. Model based on the alignment was
constructed using the Modeller module of InsightII. Based on
these structures, S9 was docked into the binding site of PI3K-a,
mTOR, and tubulin with AutoDock 3.0 program [33], respec-
tively. In each ligand-receptor docking procedure, 20 different
docking solutions were obtained and the most possible binding
conformations of S9 with enzymes were determined based on the
combination of experimental information and free energy scores.
Sulforhodamine B (SRB) Assay
The anti-proliferative effect of S9 in a panel of tumor cells was
examined with the SRB assay as described [26].
In vivo Antitumor Activity Assay
Animal experiments were performed according to institutional
ethical guidelines of animal care. Well-developed tumors were cut
into 1-mm
3 fragments and transplanted s.c. into the right flank of
nude mice using a trocar. When the tumor volume reached 100 to
150 mm
3, the mice were randomly assigned into control and
treatment groups. Control groups were given vehicle alone, and
treatment groups received S9 as indicated doses via i.p.
administration five days per week for 2 weeks. The sizes of the
tumors were measured twice per week using microcaliper. The
tumor volume (TV) was calculated as: TV = (length6width
2)/2.
The tumor volume on day n was expressed as relative tumor
volume (RTV) calculated with formula RTV = TVn/TV0, where
TVn is the volume on day n, and TV0 is the volume at the
beginning of the treatment. The therapeutic effect of the
compounds on day 14 was presented as T/C values, which were
calculated as: T/C = mean RTV of the treated group / mean
RTV of the control group.
Data Analysis Statistics
Data were presented as X6SD, and differences were considered
significant when P,0.05 as determined by Student’s t test.
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